Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma
Source Saito et al., 2019 · Keio University Faculty of Pharmacy, Division of Pharmacotherapeutics · 10.1016/j.celrep.2019.03.088
Abstract
This protocol describes the establishment and long-term in vitro culture of organoids derived from biliary tract carcinoma (BTC) tissues, including intrahepatic cholangiocarcinoma, gallbladder cancer, and neuroendocrine carcinoma of the ampulla of Vater. The organoids recapitulate histopathology, gene expression, and genetic alterations of primary tumors and enable identification of prognostic biomarkers and therapeutic agents through drug screening.
Protocol overview
22 steps across 6 phases
- 1 Tissue sectioning
- 2 Enzymatic digestion
- 3 Cell collection and washing
- 1 Matrigel embedding
- 2 Allow Matrigel to solidify
- 3 Add culture medium
- 1 Monitor organoid formation
- 2 Medium change
- 3 Organoid passaging
- 4 Long-term culture maintenance
- 1 Organoid plating for drug screening
- 2 Compound addition
- 3 Cell viability assessment
- 4 Data analysis and interpretation
- 1 RNA extraction for gene expression profiling
- 2 Microarray analysis
- 3 DNA extraction for whole-exome sequencing
- 4 Whole-exome sequencing
- 1 Tissue fixation and embedding
- 2 H&E and PAS staining
- 3 Immunohistochemistry
- 4 Microscopic examination and documentation
Full SOP
Create a free account to access this protocol
Join OrganMatch to unlock step-by-step procedures, reagent concentrations, QC checklists, and downloadable batch record templates.
Create free accountAlready registered? Log in
Attribution
This SOP was authored by Organthis based on the published method in Saito et al., 2019. The originating laboratory holds no rights in this SOP and has not endorsed it unless marked Verified.
This wording is awaiting legal review.
Something wrong with this entry? Report an issue with this protocol